Slamming the Courthouse Door: No Review of Alleged Statutory Violations in Task Order Procurements
Client Alert | less than 1 min read | 09.19.14
In SRA In'l v. U.S. (Sept. 15, 2014), the Federal Circuit held that the Court of Federal Claims lacked jurisdiction over a protest of an agency's OCI waiver made in the context of a task order procurement. The Federal Circuit found that the divestiture of jurisdiction over task order procurements in the Federal Acquisition Streamlining Act is complete and does not have an exception for alleged violations of statute or regulation.
Insights
Client Alert | 9 min read | 10.21.26
The life sciences sector is uniquely vulnerable to the inherent risks of AI-generated evidence in drug development and discovery. This client alert focuses on five core challenges: hallucinations, skewed predictions from unrepresentative training data, the opacity of AI reasoning, input sensitivity that undermines reproducibility, and adversarial manipulation of training data. To address these risks, companies should use experimental validation and human oversight as the common legal and regulatory safety net. This entails among other measures auditing AI outputs, characterizing training data, and structural oversight. Companies also should prepare for evolving frameworks and guidance from the U.S. Food and Drug Administration (FDA) and the European Union (EU) that address use of AI in drug discovery and development .
Client Alert | 2 min read | 10.21.26
Client Alert | 3 min read | 10.21.26
Private Investigations Act Series: Temporal, material and territorial scope
Client Alert | 7 min read | 10.21.26
